Anhydrous cosmetic composition comprising an endolysin derived from Staphylococcus aureus phage and mannitol.

An anhydrous composition with endolysin and mannitol stabilizes the endolysin, addressing stability issues and maintaining antimicrobial efficacy against S. aureus, effectively treating skin disorders.

FR3149201B1Active Publication Date: 2026-04-03LOREAL SA
0 Cites 0 Cited by

Patent Information

Application Number
FR2023005545
Authority / Receiving Office
FR · FR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2026-04-03
Estimated Expiration
2043-06-02

AI Technical Summary

Technical Problem

Existing endolysins targeting Staphylococcus aureus face stability issues in formulations, particularly in aqueous solutions, leading to loss of lytic activity over time and temperature, and there is a need for a formulation that maintains their antimicrobial efficacy while preserving the specificity for the targeted bacteria.

Method used

An anhydrous composition comprising endolysin derived from Staphylococcus aureus phage with at least 80% sequence identity and mannitol stabilizes the endolysin, maintaining its activity for extended periods at room temperature and high temperatures.

Benefits of technology

The combination of endolysin and mannitol in an anhydrous form retains S. aureus-killing performance even after storage for weeks at room temperature and at elevated temperatures, ensuring effective treatment of skin disorders related to S. aureus colonization.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

An anhydrous composition comprising an endolysin derived from a Staphylococcus aureus phage and mannitol. The present invention relates to an anhydrous composition comprising (i) at least one endolysin derived from a Staphylococcus aureus phage; and (ii) mannitol, the endolysin comprising a protein sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of the reference amino acid sequences SEQ ID NO: 1 and SEQ ID NO: 2. It also relates to a composition comprising, in a physiologically acceptable medium, at least one anhydrous composition of the invention.It also covers the use of such a composition to prevent and / or treat a skin disorder related to Staphylococcus aureus colonization in an individual in need, and a non-therapeutic cosmetic process for the care of keratinous materials comprising at least one step of topical application of such a composition to said keratinous materials. Finally, it covers a process for stabilizing an endolysin derived from a Staphylococcus aureus phage. Figure for the abstract: None.
Need to check novelty before this filing date? Find Prior Art